Respiratory syncytial virus - RSV 200 full text articles free

Respiratory Syncytial Virus
Nancy Bernal, Shan Kuang, Sahar Yaftaly
Respiratory Syncytial Virus.ppt

What is RSV?
Sarah Carrante, Veronica Cavera, Marlena Piehler, Kirsten Tandberg
What is RSV?.ppt

Virus-Induced Immunopathology
Immunopathology.ppt

Respiratory Syncytial Virus
Respiratory Syncytial Virus.ppt

Viral Diseases of the Respiratory System
Louise S. Thai, M.D.
Viral Diseases of the Respiratory System.ppt

Viral Pneumonia
Viral_Pneumonia_cpirozzi.ppt

Introduction to RNA interference
Toumazos Theodorou
RNAi.ppt

Respiratory Syncytial Virus
Sonia Leng, Heather Leonard
RSV.ppt

Respiratory Syncytial Virus
Rachael McClurg, Ridhi Mehta, Eun Hye Kim
RSvirus.ppt

RSV Bronchiolitis
Mark A. Brown, M.D.
RSV Bronchiolitis.ppt

Immunoprophylaxis for Prevention of Severe RSV Bronchiolitis
Ma. Teresa C. Ambat, MD
RSV Bronchiolitis .ppt

Respiratory Syncytial Virus
Rsv.ppt

Respiratory Syncytial Virus Bronchiolitis in Infants
Amanda Snodgrass, Dr. Bill Grimes
Respiratory Syncytial Virus Bronchiolitis in Infants.ppt

Respiratory Syncytial Virus: Beyond fluids and oxygen
Joseph Y. Allen, MD
Respiratory_Syncytial_Virus_Talk.ppt
200 free full text articles

1. Residential crowding and severe respiratory syncytial virus disease among infants and young children: A systematic literature review.
2. The respiratory syncytial virus g protein conserved domain induces a persistent and protective antibody response in rodents.
3. Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?
4. Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.
5. Genetic variability of human respiratory syncytial virus a strains circulating in ontario: a novel genotype with a 72 nucleotide g gene duplication.
6. One-step multiplex real time RT-PCR for the detection of bovine respiratory syncytial virus, bovine herpesvirus 1 and bovine parainfluenza virus 3.
7. Quantitative trait Loci associated with the immune response to a bovine respiratory syncytial virus vaccine.
8. Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children - a ten year perspective.
9. Differential expression of cytokines in response to respiratory syncytial virus infection of calves with high or low circulating 25-hydroxyvitamin D3.
10. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice.
11. Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant.
12. Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection.
13. Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.
14. Respiratory syncytial virus, infants and intensive therapy.
15. The human respiratory syncytial virus non-structural protein 1 regulates type I and type II interferon pathways.
16. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles.
17. TLR2/MyD88/NF-κB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection.
18. Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010.
19. Respiratory syncytial virus infection in children with neuromuscular impairment.
20. Risk factors for severe respiratory syncytial virus lower respiratory tract infection.
21. Epidemiology of respiratory syncytial virus infection in preterm infants.
22. Diagnosis of respiratory syncytial virus infection.
23. Respiratory syncytial virus infection in high-risk infants.
24. Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection.
25. Effect of respiratory syncytial virus infection on regulated on activation, normal T-cells expressed and secreted production in a murine model of asthma.
26. Comparison of direct fluorescence assay and real-time rt-PCR as diagnostics for respiratory syncytial virus in young children.
27. What happens when you mix a transplant with respiratory syncytial virus?
28. Neonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice.
29. The Anti-Apoptotic Effect of Respiratory Syncytial Virus on Human Peripheral Blood Neutrophils is Mediated by a Monocyte Derived Soluble Factor.
30. Relationship between the population incidence of febrile convulsions in young children in Sydney, Australia and seasonal epidemics of influenza and respiratory syncytial virus, 2003-2010: a time series analysis.
31. Severity of viral coinfection in hospitalized infants with respiratory syncytial virus infection.
32. Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008.
33. Whole genome sequencing and evolutionary analysis of human respiratory syncytial virus A and B from Milwaukee, WI 1998-2010.
34. Exploratory Spatial Analysis of in vitro Respiratory Syncytial Virus Co-infections.
35. Immunoprotectivity of HLA-A2 CTL peptides derived from respiratory syncytial virus fusion protein in HLA-A2 transgenic mouse.
36. The insertion of fluorescent proteins in a variable region of respiratory syncytial virus L polymerase results in fluorescent and functional enzymes but with reduced activities.
37. Relationship between lower respiratory tract infections caused by respiratory syncytial virus and subsequent development of asthma in Japanese children.
38. Label-free quantitative proteomics reveals regulation of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) and 5'-3'-exoribonuclease 2 (XRN2) during respiratory syncytial virus infection.
39. Requirements for Human Respiratory Syncytial Virus Glycoproteins in Assembly and Egress from Infected Cells.
40. Evaluation of protective efficacy of respiratory syncytial virus vaccine against A and B subgroup human isolates in Korea.
41. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze.
42. Prenatal prevention of respiratory syncytial virus bronchiolitis.
43. Respiratory syncytial virus--United States, July 2007-June 2011.
44. A study of the genetic variability of human respiratory syncytial virus (HRSV) in Cambodia reveals the existence of a new HRSV group B genotype.
45. Krüppel-like factor 6 regulates transforming growth factor-β gene expression during human respiratory syncytial virus infection.
46. Circulating strains of human respiratory syncytial virus in central and south America.
47. Respiratory syncytial virus prevention in children with congenital heart disease: who and how?
48. Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey.
49. Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus.
50. Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs.
51. Characterization of the interaction between human respiratory syncytial virus and the cell cycle in continuous cell culture and primary human airway epithelial cells.
52. Major histocompatibility complex-dependent cytotoxic T lymphocyte repertoire and functional avidity contribute to strain-specific disease susceptibility after murine respiratory syncytial virus infection.
53. Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location.
54. Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation.
55. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
56. Respiratory syncytial virus binds and undergoes transcription in neutrophils from the blood and airways of infants with severe bronchiolitis.
57. Systemic signature of the lung response to respiratory syncytial virus infection.
58. Low CCR7-mediated migration of human monocyte derived dendritic cells in response to human respiratory syncytial virus and human metapneumovirus.
59. Replacement of previously circulating respiratory syncytial virus subtype B strains with the BA genotype in South Africa.
60. Identification of deletion mutant respiratory syncytial virus strains lacking most of the G protein in immunocompromised children with pneumonia in South Africa.
61. Severity of viral coinfection in hospitalized infants with respiratory syncytial virus infection.
62. Relationship between RANTES polymorphisms and respiratory syncytial virus bronchiolitis in a Japanese infant population.
63. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.
64. Respiratory syncytial virus infection as a precipitant of thyroid storm in a previously undiagnosed case of graves' disease in a prepubertal girl.
65. Mutation of the elongin C binding domain of human respiratory syncytial virus non-structural protein 1 (NS1) results in degradation of NS1 and attenuation of the virus.
66. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
67. A nuclear factor-κB signaling pathway via protein kinase C δ regulates replication of respiratory syncytial virus in polarized normal human nasal epithelial cells.
68. A Classification Study of Respiratory Syncytial Virus (RSV) Inhibitors by Variable Selection with Random Forest.
69. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response.
70. Current progress on development of respiratory syncytial virus vaccine.
71. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
72. Modeling the variations in pediatric respiratory syncytial virus seasonal epidemics.
73. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV).
74. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.
75. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice.
76. Acute lower respiratory tract infection due to respiratory syncytial virus in a group of Egyptian children under 5 years of age.
77. Human respiratory syncytial virus in children hospitalized for acute lower respiratory infection.
78. Hot topics in the prevention of respiratory syncytial virus disease.
79. Bimodal effects of obesity ratio on disease duration of respiratory syncytial virus infection in children.
80. Respiratory syncytial virus: a prioritized or neglected target?
81. [Effect of polyI: C on secretion of thymic stromal lymphopoietin and airway inflammation in mice with respiratory syncytial virus-induced asthma exacerbation].
82. Inhaled ribavirin therapy in adult respiratory syncytial virus-induced acute respiratory distress syndrome.
83. Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus.
84. A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression.
85. Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease.
86. [Paroxysmal supraventricular tachycardia and severe respiratory syncytial virus infection in the neonatal period].
87. Large-scale seroprevalence analysis of human metapneumovirus and human respiratory syncytial virus infections in Beijing, China.
88. Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus a2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses.
89. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.
90. Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.
91. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
92. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
93. Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells.
94. Respiratory syncytial virus infection.
95. Respiratory syncytial virus infection in children.
96. Recombinant Sendai viruses expressing fusion proteins with two furin cleavage sites mimic the syncytial and receptor-independent infection properties of respiratory syncytial virus.
97. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
98. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.
99. Respiratory syncytial virus represses glucocorticoid receptor-mediated gene activation.
100. Evaluation of the 3M rapid detection test for respiratory syncytial virus (RSV) in children during the early stages of the 2009 RSV season.
101. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand.
102. The use of a neonatal mouse model to study respiratory syncytial virus infections.
103. Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells.
104. T Cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection.
105. Right ventricular function in children with severe respiratory syncytial virus (RSV) bronchiolitis.
106. Genotyping and phylogenetic analysis of the major genes in respiratory syncytial virus isolated from infants with bronchiolitis.
107. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.
108. Predicting the start week of respiratory syncytial virus outbreaks using real time weather variables.
109. Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study.
110. Respiratory syncytial virus infections in the adult asthmatic--mechanisms of host susceptibility and viral subversion.
111. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.
112. Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.
113. Serum antibodies critically affect virus-specific CD4+/CD8+ T cell balance during respiratory syncytial virus infections.
114. Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection.
115. Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects.
116. Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.
117. Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs.
118. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection.
119. Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent.
120. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
121. Prevention of respiratory syncytial virus infection.
122. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.
123. Therapeutic targeting of respiratory syncytial virus G-protein.
124. Creola bodies in infancy with respiratory syncytial virus bronchiolitis predict the development of asthma.
125. Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease.
126. Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease.
127. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
128. Respiratory syncytial virus induces host RNA stress granules to facilitate viral replication.
129. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice.
130. Real-time detection of influenza a, influenza B, and respiratory syncytial virus a and B in respiratory specimens by use of nanoparticle probes.
131. Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
132. Human respiratory syncytial virus in children with acute respiratory tract infections in China.
133. The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation.
134. TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus.
135. Palivizumab for the prevention of respiratory syncytial virus infection.
136. Roles of the respiratory syncytial virus trailer region: effects of mutations on genome production and stress granule formation.
137. Exhaled nitric oxide in acute respiratory syncytial virus bronchiolitis.
138. Molecular quantification of respiratory syncytial virus in respiratory samples: reliable detection during the initial phase of infection.
139. Intrapatient variation of the respiratory syncytial virus attachment protein gene.
140. Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein.
141. Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus.
142. Respiratory syncytial virus encephalitis with symmetrical bilateral hemispheric lesions in an adult.
143. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection.
144. Identification of adenovirus, influenza virus, parainfluenza virus, and respiratory syncytial virus by two kinds of multiplex polymerase chain reaction (PCR) and a shell vial culture in pediatric patients with viral pneumonia.
145. Viral load drives disease in humans experimentally infected with respiratory syncytial virus.
146. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)].
147. Role of peroxiredoxin 1 and peroxiredoxin 4 in protection of respiratory syncytial virus-induced cysteinyl oxidation of nuclear cytoskeletal proteins.
148. New genotypes within respiratory syncytial virus group B genotype BA in Niigata, Japan.
149. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.
150. Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.
151. Mapping the anatomy of respiratory syncytial virus infection of the upper airways in chinchillas (Chinchilla lanigera).
152. CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection.
153. Age-dependent differences in the pathogenesis of bovine respiratory syncytial virus infections related to the development of natural immunocompetence.
154. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis.
155. [Co-infection by respiratory syncytial virus and invasive meningococcal disease].
156. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.
157. Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly.
158. Palivizumab-resistant human respiratory syncytial virus infection in infancy.
159. The relationship between antibody status to bovine corona virus and bovine respiratory syncytial virus and disease incidence, reproduction and herd characteristics in dairy herds.
160. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
161. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats.
162. Association of IL-13 in respiratory syncytial virus-induced pulmonary disease: still a promising target.
163. Respiratory syncytial virus limits alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and viral replication.
164. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
165. Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene.
166. Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.
167. [Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology.].
168. Spatial patterns of bovine corona virus and bovine respiratory syncytial virus in the Swedish beef cattle population.
169. Evidence that the polymerase of respiratory syncytial virus initiates RNA replication in a nontemplated fashion.
170. Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability.
171. Respiratory syncytial virus-positive bronchiolitis in hospitalized infants is associated with thrombocytosis.
172. Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus.
173. Causal direction between respiratory syncytial virus bronchiolitis and asthma studied in monozygotic twins.
174. [Respiratory syncytial virus increases the expression and release of high mobility group Box-1 protein in the lung tissue of mice].
175. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.
176. Narcissus tazetta lectin shows strong inhibitory effects against respiratory syncytial virus, influenza A (H1N1, H3N2, H5N1) and B viruses.
177. Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis.
178. Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta.
179. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.
180. Should the American Academy of Pediatrics respiratory syncytial virus guidelines be modified?
181. [Effects of different factors on the expression of thymic stromal lymphopoietin in respiratory syncytial virus-infected human airway epithelial cells].
182. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
183. Evaluation of a commercial real-time reverse transcription polymerase chain reaction kit for the diagnosis of Bovine respiratory syncytial virus infection.
184. Correlation between inflammatory mediators in the nasopharyngeal secretion and in the serum of children with lower respiratory tract infection caused by respiratory syncytial virus and disease severity.
185. Differential expression of cytokine transcripts in neonatal and adult ovine alveolar macrophages in response to respiratory syncytial virus or toll-like receptor ligation.
186. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells.
187. Respiratory syncytial virus activity - United States, July 2008-December 2009.
188. Clinical and epidemiological comparison of human metapneumovirus and respiratory syncytial virus in seoul, Korea, 2003-2008.
189. Respiratory syncytial virus infection reduces lung inflammation and fibrosis in mice exposed to vanadium pentoxide.
190. Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein.
191. Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells.
192. Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection.
193. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.
194. Inactivation of respiratory syncytial virus by zinc finger reactive compounds.
195. Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, Jordan.
196. Distribution of airborne influenza virus and respiratory syncytial virus in an urgent care medical clinic.
197. Structural basis of respiratory syncytial virus neutralization by motavizumab.
198. Duration of shedding of respiratory syncytial virus in a community study of Kenyan children.
199. Multiple, non-conserved, internal viral ligands naturally presented by HLA-B27 in human respiratory syncytial virus-infected cells.
200. Anti-inflammatory effect of MUC1 during respiratory syncytial virus infection of lung epithelial cells in vitro.